{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-105114","form_type":"8-K","ticker":"HRGN","cik":"0001563665","company_name":"Harvard Apparatus Regenerative Technology, Inc.","filed_at":"2021-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.590021+00:00","generated_at":"2026-06-29T11:21:57.319553+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Biostage Q2 net loss narrows to $0.4M; cash $0.5M, funding into Q3 2021","bullets":["Net loss of $0.4M ($0.04 per share) vs $1.2M loss in Q2 2020.","Improvement due to lower R&D, lower G&A, and $0.4M PPP loan forgiveness gain.","Cash on-hand of $0.5M as of June 30, 2021; expects to fund operations into Q3 2021.","No conference call held; company plans future call for clinical and business plans."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-105114","json":"https://secwatch.observer/filing/0001104659-21-105114.json","markdown":"https://secwatch.observer/filing/0001104659-21-105114.md","text":"https://secwatch.observer/filing/0001104659-21-105114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563665/000110465921105114/0001104659-21-105114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563665/000110465921105114/tm2125067d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T11:21:57.319553+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}